Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

395 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ABO and Rh blood groups and risk of colorectal adenocarcinoma.
Urun Y, Ozdemir NY, Utkan G, Akbulut H, Savas B, Oksuzoglu B, Oztuna DG, Dogan I, Yalcin B, Senler FC, Onur H, Demirkazik A, Zengin N, Icli F. Urun Y, et al. Among authors: dogan i. Asian Pac J Cancer Prev. 2012;13(12):6097-100. doi: 10.7314/apjcp.2012.13.12.6097. Asian Pac J Cancer Prev. 2012. PMID: 23464411 Free article.
Adjuvant Treatment of Gastric Cancer in the D2 Dissection Era: A Real-life Experience from a Multicenter Retrospective Cohort Study.
Yekedüz E, Doğan İ, Birgi SD, Keskin M, Karaman Ş, Utkan G, Karabulut S, Bayar S, Akbulut H, Demirci S, Akyürek S, Ürün Y. Yekedüz E, et al. Among authors: dogan i. Euroasian J Hepatogastroenterol. 2021 Jul-Dec;11(2):51-58. doi: 10.5005/jp-journals-10018-1343. Euroasian J Hepatogastroenterol. 2021. PMID: 34786357 Free PMC article.
CONCLUSION: In this real-life study, we established that there was no additional benefit of RT in GC patients who underwent D2 dissection. HOW TO CITE THIS ARTICLE: Yekeduz E, Dogan I, Birgi SD, et al. Adjuvant Treatment of Gastric Cancer in the D2 Dissection Era: A …
CONCLUSION: In this real-life study, we established that there was no additional benefit of RT in GC patients who underwent D2 dissection. H …
Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study.
Bilgin B, Sendur MAN, Yucel S, Celik E, Ozyukseler DT, Ayhan M, Basoglu T, Ilhan A, Akdeniz N, Gulmez A, Dogan I, Aktas BY, Gurbuz M, Koca S, Paydas S, Tatli AM, Cinkir HY, Alan O, Erol C, Hizal M, Kut E, Menevse S, Sakalar T, Taskaynatan H, Deniz GI, Karaagac M, Avci O, Sen E, Karatas F, Akinci MB, Dede DS, Demir A, Demirkazık A, Oksuzoglu B, Kilickap S, Yumuk F, Yalcin B. Bilgin B, et al. Among authors: dogan i. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6. Epub 2021 Jan 12. J Cancer Res Clin Oncol. 2021. PMID: 33433657
395 results